REQUEST A DEMO
Total
USD $0.00
Search more companies

Sk Biopharmaceuticals Co.,Ltd. (Seongnam) (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Sk Biopharmaceuticals Co.,Ltd. Profile Updated: March 25, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Sk Biopharmaceuticals Co.,Ltd. (Seongnam) is an enterprise based in South Korea. Its main office is in Seongnam. It operates in the Research and Development in Nanotechnology industry. It was incorporated on April 01, 2011. 272 (2025) employees currently work for Sk Biopharmaceuticals Co.,Ltd. (Seongnam). In Q12026, the company reported a net sales revenue increase of 57.84%. Its’ total assets recorded a growth of 31.77%. In 2026, Sk Biopharmaceuticals Co.,Ltd. (Seongnam)’s net profit margin increased by 31.49%.

Headquarters
221, Pangyoyeok-Ro, Bundang-Gu
Seongnam; Gyeonggi;

Contact Details: Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.

Website: http://www.skbp.com

Basic Information
Total Employees:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Outstanding Shares:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Registered Capital:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Financial Auditors:
Purchase the Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report to view the information.
Incorporation Date:
April 01, 2011
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
에스케이
Company Performance
Financial values in the chart are available after Sk Biopharmaceuticals Co.,Ltd. (Seongnam) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
57.84%
Total Operating Revenue
66.95%
Operating Profit
359.67%
EBITDA
284.64%
Net Profit/Loss for the Period
423.55%
Total Assets
31.77%
Total Equity
57.58%
Operating Profit Margin
27.5%
Net Profit Margin
31.49%
Return on Equity (ROE)
7.7%
Debt / Equity
-15.72%
Quick Ratio
0.7%
Cash Ratio
0.18%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?